A neuroprotective polypeptide compound and its application

通过组合β-丙氨酸、组氨酸及其衍生物与NR2B9c活性肽,开发的神经保护多肽化合物能够穿越血脑屏障,解决了现有神经保护剂难以穿越屏障的问题,实现了对脑卒中 Effective treatment of neurological diseases, and the dose is small, and the effect is significant.

CN113735938BActive Publication Date: 2024-11-08WUHAN INNERSE PHARMA
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
CN202110873573.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-07-30
Publication Date
2024-11-08
Estimated Expiration
2041-07-30

AI Technical Summary

Technical Problem

Existing neuroprotective agents, such as carnosine and their derivatives, require large doses and are not effective in using alone, making them difficult to effectively cross the blood-brain barrier and cannot effectively treat neurological diseases, especially stroke.

Method used

A neuroprotective polypeptide compound was developed. By combining β-alanine, histidine and its derivatives with NR2B9c active peptides, the peptide formed can cross the blood-brain barrier and be administered through intravenous routes, demonstrating good biological activity. , used to treat neurological diseases.

Benefits of technology

This neuroprotective polypeptide compound can effectively cross the blood-brain barrier, significantly reduce the area of ​​cerebral infarction, improve the functional prognosis of stroke patients, and only a dose of 3 mg/kg can achieve the same therapeutic effect as the existing standard polypeptide NA1.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 210730170830
    Figure 210730170830
  • Figure 210730170833
    Figure 210730170833
  • Figure 210730170836
    Figure 210730170836
Patent Text Reader

Abstract

The present invention discloses a neuroprotective polypeptide compound and its application, belonging to the field of pharmaceutical technology. It includes a polypeptide and a salt thereof having the following chemical formula: (M)m-(Lys-Leu-Ser-Ser-Ile-Glu / Asp-Ser / Thr-Asp / Glu-Val / Leu)-(N)n; m and n are integers of 0-3, but m and n are not zero at the same time; M is beta-Ala-His, beta-Ala-1-Methyl-His or beta-Ala-3-Methyl-His, and N is beta-Ala-His, beta-Ala-1-Methyl-His or beta-Ala-3-Methyl-His. Only an intravenous injection dose of 3 mg / kg is required, and a significant therapeutic effect can be unexpectedly achieved, which is the same effect as NA1.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical technology, and particularly relates to a neuroprotective polypeptide compound and application thereof. Background Art

[0002] Nerinetide (NA-1) is a neuroprotective agent that interferes with postsynaptic density protein 95 (PSD-95) by terminating the production of intracellular NO free radicals. It can reduce the infarct size of cerebral ischemia-reperfusion and improve its functional prognosis in preclinical ischemic stroke models. Adult patients with acute ischemic stroke due to large vessel occlusion within a 12-hour treatment window were randomized to receive a single dose of 2.6 mg / kg of Nerinetide, with a maximum dose of 270 mg, or a saline placebo. The primary endpoint of the study was a good functional prognosis 90 days after randomization, defined as a modified Rankin Scale (MRS) score of 0-2 points, and secondary endpoints were neurological disability, functional independence in activities of daily living, good functional outcomes (mRS0-1), and mortality. A total of 1,105 patients participated in the trial, including 549 in the Nerinetide group and 556 in the placebo group. The proportion of patients with mRS scores of 0-2 within 90 days was: 337 (61.4%) in the nerinetide group and 329 (59.2%) in the placebo group. The secondary outcomes were similar between the two groups. At the same time, this study found that nerinetide treatment led to the inhibition of the effect of alteplase in patients receiving alteplase. The incidence of serious adverse events was the same between the two groups. (Michael D Hill et al. Efficacy and safety of nerinetide for the treatment of acute ischaemicstroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet. 2020, 395 (10227), P878-887).

[0003] Nerinetide is a fusion peptide composed of 9 residues at the C-terminus of the NMDAR GluN2B subunit and the transmembrane peptide TAT derived from the nuclear transport activating protein. It can bind to the PDZ-1 or PDZ-2 domain of PSD95, thereby inhibiting the production of NO by nNOS, so it is also called Tat-NR2B9c. Its specific amino acid sequence is: Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu- Ser-Asp-Val. The latter sequence Lys-Leu-Ser-Ser-Ile-Glu- Ser-Asp-Val is the sequence of NR2B9c, which specifically inhibits the production of NO by nNOS. The front part Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg improves the bioavailability of NR2B9c. The amino acid sequence of active peptides like NR2B9c consists of 3-25 amino acids from the C-terminus of the NMDA receptor or PDZ domain 1 and / or 2 from the PSD-95 receptor connected to the internalization peptide (A. Tasker, T. Doucette, M. Tymianski, K. Mendoza, MP Belmares, D. Garman, and PS Lu, 2013, United States Patent 8,536,129). This type of active peptide has an amino acid sequence containing [E / D / N / Q]-[S / T]-[D / E / Q / N]-[V / L], such as KLSSIETDV and KLSSIESDV.

[0004] Carnosine (L-Carnosine) is a dipeptide composed of two amino acids, β-alanine and L-histidine. Carnosine has strong antioxidant capacity and is beneficial to the human body. Carnosine has been shown to remove reactive oxygen free radicals (ROS) and α-β unsaturated aldehydes formed by excessive oxidation of fatty acids in cell membranes during oxidative stress. Carnosine has anti-inflammatory, anti-glycation, antioxidant and chelating effects. It can be used as an over-the-counter food supplement and has good prospects in the prevention and adjuvant treatment of chronic diseases such as cardiovascular disease and neurodegeneration. In animal experiments, the neuroprotective mechanism of carnosine can prevent permanent cerebral ischemia. Carnosine is also an important intracellular antioxidant. Carnosine is not only non-toxic, but also has strong antioxidant properties. Therefore, it has attracted widespread attention as a new type of food additive and medicinal agent. Carnosine participates in intracellular peroxidation reactions. In addition to inhibiting the peroxidation process of cell membranes, it can also inhibit related peroxidation reactions in cells. In 1900, Russian scholar Gulewitsch first discovered carnosine. Later, scholars from various countries extracted and separated other histidine dipeptide derivatives from different muscle tissues, such as anserine, which is a dipeptide composed of two amino acids, β-alanine and 1-methyl-L-histidine, and whale carnosine or snake carnosine (Balenine, also known as Ophidine,), which is a dipeptide composed of β-alanine and 3-methyl-L-histidine. The content of these carnosine and carnosine derivatives in different animals is also different, and the content and proportion of these histidine dipeptides between different species are also different, with certain specificity. In addition to the presence of histidine dipeptides in muscle tissue, these dipeptides also exist in other tissues, such as brain tissue. These carnosine derivatives are water-soluble and strong, and have significant antioxidant, anti-aging, and uric acid-lowering functions. They have been used as natural antioxidants and uric acid-lowering diet therapy in the food industry, and also have certain neuroprotective functions.

[0005] Although carnosine and carnosine derivatives have certain brain protective effects, they often require larger doses. The effects of using carnosine, anserine and snake carnosine alone are not good. We combined carnosine and carnosine derivatives with active peptides such as NR2B9c to create a new type of polypeptide in this patent. We found that this new combination of polypeptides has good neuroprotective effects, thus providing a new method for neuroprotection. Summary of the invention

[0006] The present invention provides a neuroprotective polypeptide compound, which is composed of beta-alanine and histidine, 1-methylhistidine or 3-methylhistidine, etc., carnosine, anserine, snake carnosine, etc., and an active peptide represented by NR2B9c, the amino acid sequence of the active peptide is Lys-Leu-Ser-Ser-Ile-Glu / Asp-Ser / Thr-Asp / Glu-Val / Leu, especially NR2B9c Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val, thereby forming a series of combined polypeptide compounds with the characteristics of carnosine, anserine or snake carnosine and Lys-Leu-Ser-Ser-Ile-Glu / Asp-Ser / Thr-Asp / Glu-Val / Leu. These peptides unexpectedly pass through the blood-brain barrier and show good biological activity through intravenous administration, thus showing broad prospects in the treatment of nervous system diseases, especially brain damage and stroke. The technical scheme is as follows:

[0007] In one aspect, the present invention provides a neuroprotective polypeptide compound, including a polypeptide having the following chemical formula and a salt thereof:

[0008] (M)m-(Lys-Leu-Ser-Ser-Ile-Glu / Asp-Ser / Thr-Asp / Glu-Val / Leu)-(N)n

[0009] Wherein, m is an integer of 0-3, n is an integer of 0-3, but m and n are not zero at the same time; M is beta-Ala-His, beta-Ala-1-Methyl-His or beta-Ala-3-Methyl-His, and N is beta-Ala-His, beta-Ala-1-Methyl-His or beta-Ala-3-Methyl-His. Glu / Asp means that the amino acid at this position can be either Glu or Asp, Ser / Thr means that the amino acid at this position can be either Ser or Thr, Asp / Glu means that the amino acid at this position can be either Asp or Glu, and Val / Leu means that the amino acid at this position can be either Val or Leu.

[0010] Preferably, Lys-Leu-Ser-Ser-Ile-Glu / Asp-Ser / Thr-Asp / Glu-Val / Leu is Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val.

[0011] The neuroprotective polypeptide compounds of the present invention include polypeptides having the following chemical formula and salts thereof:

[0012] beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu / Asp-Ser / Thr-Asp / Glu-Val / Leu;

[0013] Lys-Leu-Ser-Ser-Ile-Glu / Asp-Ser / Thr-Asp / Glu-Val / Leu-beta-Ala-His;

[0014] beta-Ala-His-beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu / Asp-Ser / Thr-Asp-Val / Leu;

[0015] Lys-Leu-Ser-Ser-Ile-Glu / Asp-Ser / Thr-Asp / Glu-Val / Leu-beta-Ala-His-beta-Ala-His;

[0016] beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu / Asp-Ser / Thr-Asp / Glu-Val / Leu-beta-Ala-His;

[0017] beta-Ala-His-beta-Ala-His-beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu / Asp-Ser / Thr-Asp-Val / Leu;

[0018] beta-Ala-His-beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu / Asp-Ser / Thr-Asp-Val / Leu-beta-Ala-His;

[0019] beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu / Asp-Ser / Thr-Asp / Glu-Val / Leu-beta-Ala-His-beta-Ala-His;

[0020] Lys-Leu-Ser-Ser-Ile-Glu / Asp-Ser / Thr-Asp / Glu-Val / Leu-beta-Ala-His-beta-Ala-His-beta-Ala-His;

[0021] Wherein, His is His, 1-Methyl-His or 3-Methyl-His corresponding to carnosine, anserine and snake carnosine respectively.

[0022] Specifically, the neuroprotective polypeptide compounds of the present invention include polypeptides having the following chemical formula and salts thereof:

[0023] beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val;

[0024] beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Asp-Ser-Asp-Val;

[0025] beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu-Thr-Asp-Val;

[0026] beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu-Thr-Glu-Val;

[0027] beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Glu-Val;

[0028] beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Asp-Thr-Asp-Val;

[0029] beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Asp-Ser-Glu-Val;

[0030] beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Asp-Thr-Glu-Val;

[0031] Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-beta-Ala-His;

[0032] Lys-Leu-Ser-Ser-Ile-Asp-Ser-Asp-Val-beta-Ala-His;

[0033] Lys-Leu-Ser-Ser-Ile-Glu-Thr-Asp-Val-beta-Ala-His;

[0034] Lys-Leu-Ser-Ser-Ile-Glu-Thr-Glu-Val-beta-Ala-His;

[0035] Lys-Leu-Ser-Ser-Ile-Glu-Ser-Glu-Val-beta-Ala-His;

[0036] Lys-Leu-Ser-Ser-Ile-Asp-Thr-Asp-Val-beta-Ala-His;

[0037] Lys-Leu-Ser-Ser-Ile-Asp-Ser-Glu-Val-beta-Ala-His;

[0038] Lys-Leu-Ser-Ser-Ile-Asp-Thr-Glu-Val-beta-Ala-His;

[0039] beta-Ala-(1-methyl-His)-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val;

[0040] beta-Ala-(1-methyl-His)-Lys-Leu-Ser-Ser-Ile-Asp-Ser-Asp-Val;

[0041] beta-Ala-(1-Methyl-His)-Lys-Leu-Ser-Ser-Ile-Glu-Thr-Asp-Val;

[0042] beta-Ala-(1-Methyl-His)-Lys-Leu-Ser-Ser-Ile-Glu-Thr-Glu-Val;

[0043] beta-Ala-(1-Methyl-His)-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Glu-Val;

[0044] beta-Ala-(1-Methyl-His)-Lys-Leu-Ser-Ser-Ile-Asp-Thr-Asp-Val;

[0045] beta-Ala-(1-Methyl-His)-Lys-Leu-Ser-Ser-Ile-Asp-Ser-Glu-Val;

[0046] beta-Ala-(1-Methyl-His)-Lys-Leu-Ser-Ser-Ile-Asp-Thr-Glu-Val;

[0047] Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-beta-Ala-(1-Methyl-His);

[0048] Lys-Leu-Ser-Ser-Ile-Asp-Ser-Asp-Val-beta-Ala-(1-Methyl-His);

[0049] Lys-Leu-Ser-Ser-Ile-Glu-Thr-Asp-Val-beta-Ala-(1-Methyl-His);

[0050] Lys-Leu-Ser-Ser-Ile-Glu-Thr-Glu-Val-beta-Ala-(1-Methyl-His);

[0051] Lys-Leu-Ser-Ser-Ile-Glu-Ser-Glu-Val-beta-Ala-(1-Methyl-His);

[0052] Lys-Leu-Ser-Ser-Ile-Asp-Thr-Asp-Val-beta-Ala-(1-Methyl-His);

[0053] Lys-Leu-Ser-Ser-Ile-Asp-Ser-Glu-Val-beta-Ala-(1-Methyl-His);

[0054] Lys-Leu-Ser-Ser-Ile-Asp-Thr-Glu-Val-beta-Ala-(1-Methyl-His);

[0055] beta-Ala-(3-methyl-His)-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val;

[0056] beta-Ala-(3-methyl-His)-Lys-Leu-Ser-Ser-Ile-Asp-Ser-Asp-Val;

[0057] beta-Ala-(3-Methyl-His)-Lys-Leu-Ser-Ser-Ile-Glu-Thr-Asp-Val;

[0058] beta-Ala-(3-Methyl-His)-Lys-Leu-Ser-Ser-Ile-Glu-Thr-Glu-Val;

[0059] beta-Ala-(3-Methyl-His)-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Glu-Val;

[0060] beta-Ala-(3-Methyl-His)-Lys-Leu-Ser-Ser-Ile-Asp-Thr-Asp-Val;

[0061] beta-Ala-(3-Methyl-His)-Lys-Leu-Ser-Ser-Ile-Asp-Ser-Glu-Val;

[0062] beta-Ala-(3-Methyl-His)-Lys-Leu-Ser-Ser-Ile-Asp-Thr-Glu-Val;

[0063] Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-beta-Ala-(3-Methyl-His);

[0064] Lys-Leu-Ser-Ser-Ile-Asp-Ser-Asp-Val-beta-Ala-(3-Methyl-His);

[0065] Lys-Leu-Ser-Ser-Ile-Glu-Thr-Asp-Val-beta-Ala-(3-Methyl-His);

[0066] Lys-Leu-Ser-Ser-Ile-Glu-Thr-Glu-Val-beta-Ala-(3-Methyl-His);

[0067] Lys-Leu-Ser-Ser-Ile-Glu-Ser-Glu-Val-beta-Ala-(3-Methyl-His);

[0068] Lys-Leu-Ser-Ser-Ile-Asp-Thr-Asp-Val-beta-Ala-(3-Methyl-His);

[0069] Lys-Leu-Ser-Ser-Ile-Asp-Ser-Glu-Val-beta-Ala-(3-Methyl-His);

[0070] Lys-Leu-Ser-Ser-Ile-Asp-Thr-Glu-Val-beta-Ala-(3-Methyl-His).

[0071] Preferably, the neuroprotective polypeptide compounds of the present invention include polypeptides having the following chemical formula and salts thereof:

[0072] beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val;

[0073] Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-beta-Ala-His;

[0074] beta-Ala-(1-methyl-His)-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val;

[0075] Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-beta-Ala-(1-Methyl-His);

[0076] beta-Ala-(3-methyl-His)-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val;

[0077] Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-beta-Ala-(3-Methyl-His).

[0078] More preferably, the neuroprotective polypeptide compounds of the present invention include polypeptides having the following chemical formula and salts thereof:

[0079] beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val;

[0080] Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-beta-Ala-His.

[0081] Most preferably, the neuroprotective polypeptide compounds of the present invention include polypeptides having the following chemical formula and salts thereof:

[0082] beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val.

[0083] On the other hand, the present invention also provides the use of the aforementioned neuroprotective polypeptide compound in the preparation of drugs (especially drugs for treating nervous system diseases).

[0084] Specifically, the aforementioned neuroprotective polypeptide compound is used in the preparation of a drug for treating ischemic stroke, hemorrhagic stroke, brain trauma, Alzheimer's disease, Parkinson's disease or other neurodegenerative diseases. Preferably, the aforementioned neuroprotective polypeptide compound is used in the preparation of a drug for treating ischemic stroke.

[0085] Among them, the aforementioned drugs are injections, oral administration, sublingual administration, spray administration or anal administration, etc., preferably injections. Specifically, the injection is a powder injection or an injection. Further, the aforementioned drugs are administered intravenously. The aforementioned drugs can also be used as active ingredients to prepare other dosage forms for corresponding medical applications. As neuroprotective drugs, the developed preparations can include oral and sublingual preparations. As first aid drugs for stroke, the developed preparations can include spray administration, anal administration and other preparations to facilitate the treatment of patients without mobility.

[0086] Furthermore, the aforementioned medicine includes a pharmaceutically acceptable diluent and / or carrier, etc.

[0087] In another aspect, the present invention also provides a method for preparing various neuroprotective polypeptide compounds of the present invention by solid phase synthesis, but some of the peptides are more convenient to synthesize by liquid phase. Salting of polypeptide drugs is one of the common means to improve the physicochemical properties of drug molecules and enhance their drugability. The aforementioned drugs can be salts in any form.

[0088] In order to determine the application of the synthetic peptide provided by this patent in neurological diseases, the present invention uses SD rats as experimental subjects, and adopts the middle cerebral artery occlusion method (MCAO) to prepare a rat model of cerebral ischemia. The drug is injected intravenously 1-2 hours after ischemia, and behavioral observation and scoring are performed on each animal for 22-24 hours. After the behavioral observation, the experimental rats are euthanized and their brains are removed. The brain tissue sections are sliced ​​and quantified after TTC staining to calculate the volume of cerebral infarction.

[0089] The synthetic peptide of the present invention creatively combines glycine, carnosine, anserine or snake carnosine, etc., and the developed mosaic synthetic peptide unexpectedly penetrates the blood-brain barrier through intravenous injection and enters the brain, effectively playing a role in the treatment of nervous system diseases. This type of synthetic peptide is preferably used to treat ischemic stroke, hemorrhagic stroke, brain trauma, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The present invention only requires a synthetic polypeptide intravenous injection dose of 3 mg / kg, and unexpectedly can achieve a significant therapeutic effect, which is the same effect as the standard polypeptide NA1 with existing clinical activity.

[0090] Meanwhile, the synthetic peptide of the present invention is easy to synthesize. During the synthesis process, derivatives of carnosine, anserine or snake carnosine can be used as synthetic fragments to replace the corresponding two amino acids to further simplify the synthesis of the target peptide. BRIEF DESCRIPTION OF THE DRAWINGS

[0091] Figure 1 This is a cross-sectional image of the brain tissue of the model group;

[0092] Figure 2 This is a cross-sectional image of the brain tissue of the S1 group;

[0093] Figure 3 This is a cross-sectional image of the brain tissue of the S3 group;

[0094] Figure 4 This is a cross-sectional image of the brain tissue in the sham operation group. DETAILED DESCRIPTION

[0095] In order to make the objectives, technical solutions and advantages of the present invention more clear, the present invention will be further described in detail below with reference to the accompanying drawings.

[0096] Example 1: Synthesis of beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val:

[0097] 1. In the presence of an activator system (HoBT, DIC), Fmoc-Val-CTC resin is obtained by coupling solid phase support 2-CTC resin and Fmoc-Val-OH.

[0098] 2. Use 20% piperidine to remove the Fmoc protecting group on Fmoc-Val-CTC, and then wash it with DMF.

[0099] 3. Weigh 3 times excess Fmoc-Asp (0tBu) -OH and 3 times excess activator, add a small amount of DMF to fully dissolve, add to the washed resin after dissolution, react for 1 hour and then wash with DMF.

[0100] 4. Repeat the second and third steps to sequentially couple amino acids with N-terminal Fmoc protection and side chain protection from Ser to βAla in the main chain sequence.

[0101] 5. After the synthesis is completed, the cleavage is carried out. The cleavage reagent ratio is TFA: EDT: Tis: TA: anisole: H 2 O=80:5:1:5:5:4 (volume ratio), 10ml cleavage reagent is required for 1g peptide resin, cleavage is carried out at room temperature for about 2h (120r / min), and then precipitation is carried out with icy methyl tert-butyl ether. The lower precipitate is the crude product.

[0102] 6. Dissolve the crude peptide from the previous step and purify it on preparative HPLC using 0.1% TFA / acetonitrile.

[0103] 7. After purification, freeze-drying is carried out. After freeze-drying, the powder is taken out and packaged. After quality inspection, the polypeptide beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val is obtained.

[0104] Example 2: Synthesis of Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-beta-Ala-His:

[0105] 1. In the presence of an activator system (HoBT, DIC), Fmoc-His(Trt)-CTC resin is obtained by coupling the solid phase carrier 2-CTC resin and Fmoc-His(Trt)-OH.

[0106] 2. Remove the Fmoc protecting group on Fmoc-His(Trt)-CTC with 20% piperidine and wash it with DMF after removal.

[0107] 3. Weigh 3 times excess Fmoc-beta-Ala-OH and 3 times excess activator, add a small amount of DMF to fully dissolve, add to the washed resin after dissolution, react for 1 hour and then wash with DMF.

[0108] 4. Repeat the second and third steps to sequentially couple amino acids with N-terminal Fmoc protection and side chain protection from Val to Lys in the main chain sequence.

[0109] 5. After the synthesis is completed, the cleavage is carried out. The cleavage reagent ratio is TFA: EDT: Tis: TA: anisole: H 2 O=80:5:1:5:5:4 (volume ratio), 10ml cleavage reagent is required for 1g peptide resin, cleavage is carried out at room temperature for about 2h (120r / min), and then precipitation is carried out with icy methyl tert-butyl ether. The lower precipitate is the crude product.

[0110] 6. Dissolve the crude peptide from the previous step and purify it on preparative HPLC using 0.1% TFA / acetonitrile.

[0111] 7. After purification, freeze-drying is carried out. After freeze-drying, the powder is taken out and packaged. After quality inspection, the polypeptide Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-beta-Ala-His is obtained.

[0112] Example 3: Synthesis of beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-beta-Ala-His:

[0113] 1. In the presence of an activator system (HoBT, DIC), Fmoc-His(Trt)-CTC resin is obtained by coupling the solid phase carrier 2-CTC resin and Fmoc-His(Trt)-OH.

[0114] 2. Remove the Fmoc protecting group on Fmoc-His(Trt)-CTC with 20% piperidine and wash it with DMF after removal.

[0115] 3. Weigh 3 times excess Fmoc-beta-Ala-OH and 3 times excess activator, add a small amount of DMF to fully dissolve, add to the washed resin after dissolution, react for 1 hour and then wash with DMF.

[0116] 4. Repeat the second and third steps to sequentially couple amino acids with N-terminal Fmoc protection and side chain protection from Val to beta-Ala in the main chain sequence.

[0117] 5. After the synthesis is completed, the cleavage is carried out. The cleavage reagent ratio is TFA: EDT: Tis: TA: anisole: H 2 O=80:5:1:5:5:4 (volume ratio), 10ml cleavage reagent is required for 1g peptide resin, cleavage is carried out at room temperature for about 2h (120r / min), and then precipitation is carried out with icy methyl tert-butyl ether. The lower precipitate is the crude product.

[0118] 6. Dissolve the crude peptide from the previous step and purify it on preparative HPLC using 0.1% TFA / acetonitrile.

[0119] 7. After purification, freeze-drying is carried out. After freeze-drying, the powder is taken out and packaged. After quality inspection, the polypeptide beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-beta-Ala-His is obtained.

[0120] Example 4: The same method can also be used to synthesize the following peptides:

[0121] beta-Ala-(1-Methyl-His)-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val;

[0122] Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-beta-Ala-(1-Methyl-His);

[0123] beta-Ala-(1-Methyl-His)-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-beta-Ala-(1-Methyl-His);

[0124] beta-Ala-(1-Methyl-His)-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val;

[0125] Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-beta-Ala-(1-Methyl-His);

[0126] beta-Ala-(1-Methyl-His)-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-beta-Ala-(1-Methyl-His).

[0127] Example 5: Animal Experiment Methods

[0128] Small animal monitor: Shenzhen Rongxianda Technology Co., Ltd., VT200.

[0129] SD rats: China Food and Drug Identification Institute, 180-200g.

[0130] Line plug: Maiyue Biotechnology (M8507).

[0131] TTC staining solution: Source Leaf Biotechnology (R24053).

[0132] Animal model operation steps:

[0133] The experimental SD rats were weighed and anesthetized with chloral hydrate. After anesthesia, the rats' limbs were fixed, lying on their backs, and connected to a small animal monitor to monitor important physiological indicators such as body temperature, blood pressure, and heart rate. The rats' necks were depilated, and a 2-cm midline incision was made on the necks of the experimental rats after disinfection with 75% alcohol cotton balls. The submandibular glands of the rats were bluntly separated, and the glands were damaged as much as possible during the separation process. Then, the common carotid artery (CCA) on the left side of the experimental rats was bluntly separated, and the internal carotid artery (ICA) and external carotid artery (ECA) were carefully separated upward along the CCA. Avoid damaging the vagus nerve during the separation process. Use two artery clamps to clamp the CCA and ICA respectively, cut the distal end of the ECA and insert the silicone thread plug from the ECA "port". Insert it to the ICA artery clamp, loosen the artery clamp briefly and quickly insert the thread plug head through the artery clamp and clamp the ICA again, then gently loosen the artery clamp on the ICA and continue to insert the thread plug until the black mark of the thread plug passes through the bifurcation of the ECA and ICA. After the thread plug head blocks the middle cerebral artery, use sutures to tightly tie the ECA "port" and thread plug to prevent the thread plug from "withdrawing" or bleeding after the rat wakes up. Loosen and remove the artery clamps on the CCA and ICA to restore the tissue to its original position, and drip an appropriate amount of penicillin to prevent wound infection. Use a medical suture needle with thread to suture, and disinfect it again with iodine after sealing. Observe the small animal monitor to determine whether the indicators of the experimental rats are normal, and then put the rats on the small animal electric blanket to maintain body temperature until they wake up and place them in the animal cage.

[0134] Dosage process:

[0135] The drug to be tested was prepared into a 3 mg / mL solution and administered into the tail vein 1-2 hours after ligation.

[0136] When administering the drug, the rats were fixed with a fixator, and the drug to be tested was drawn up with a 1 mL syringe at a dose of 3 mg / kg, and then the rats were injected through the tail vein. The injection was slowly pushed in order to reduce the cardiopulmonary load of the experimental rats.

[0137] The animals were divided into different experimental groups, with six animals in each group.

[0138] Model group: after ligation of the tail vein, an equal amount of normal saline was administered;

[0139] Drug groups S1 (NA1) and S3 (beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val) were administered through the tail vein after ligation.

[0140] Sham operation group: The internal carotid artery (ICA) and external carotid artery (ECA) were separated but not ligated, and an equal volume of normal saline was administered into the tail vein.

[0141] Behavioral observations:

[0142] Behavioral observation and scoring were performed on each animal 22-24 h after ligation.

[0143] The following scoring table was used for blind evaluation by a technician who was not involved in the experiment.

[0144] 0 points: walking in a normal straight line;

[0145] 1 point: forelimb weakness;

[0146] 2 points: hind limb weakness;

[0147] 3 points: mild circling;

[0148] 4 points: severe circling;

[0149] 5 points: hemiplegia.

[0150] TTC staining and quantification analysis:

[0151] After behavioral observation, the experimental rats were euthanized and their brains were removed. The brain tissue was cut into 6 slices of 2 mm thickness, then transferred to TTC staining solution, incubated in a 37°C incubator in the dark for 10 min, and photographed. The TTC-stained brain tissue and the remaining small amount of brain tissue that was not TTC-stained were then stored at -20°C.

[0152] Image J software was used to perform quantitative analysis on the photos after TTC staining.

[0153] Infarct volume%=(total infarct area*slice thickness) / (total brain slice area*slice thickness)*100%.

[0154] Experimental results:

[0155] 1. TTC quantification results are shown in Table 1:

[0156] Table 1

[0157] serial number 1 2 3 4 5 6 average value Model Group 0.407 0.402 0.392 0.420 0.377 0.340 0.390 S1(NA1) 0.187 0.218 0.153 0.145 0.107 0.134 0.157 S3 0.128 0.186 0.075 0.158 0.210 0.146 0.128 Sham operation group 0.048 0.038 0.042 0.051 0.039 0.044 0.044

[0158] From the results in Table 1, it can be seen that the infarct volume of rats with cerebral ischemia injected with normal saline was 0.390±0.028, and the infarct volume of rats with cerebral ischemia injected with 3mg / kg Ala-His-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val (S3) was 0.150±0.047. The infarct volume of the sham operation group as a control was 0.044±0.005. Compared with the model group, S3 has obvious biological activity and there is no statistical difference between S3 and S1. Among them, NA1 (Nerinetide) is a neuroprotectant (Michael Tymianski and Jonathan D. Garman. Model systems and treatment regimes for treatment of neurological disease. 2015, US Patent, US8940699B2), which can interfere with postsynaptic density protein 95 (PSD-95) by terminating the production of intracellular NO free radicals. In the preclinical ischemic stroke model, it can reduce the infarct area of ​​experimental animal (macaque) cerebral ischemia-reperfusion and improve its functional prognosis. Therefore, it is a good positive control product. Dr. Hill studied the efficacy and safety of intravenous injection of the new neuropeptide NA-1 (2.6mg / kg) for patients with acute ischemic stroke (AIS) undergoing intravascular thrombectomy. The results showed that treatment with NA1 can improve patient prognosis. (Michael D Hill et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): amulticentre, double-blind, randomized controlled trial. Lancet. Publishedonline February 20, 2020).

[0159] 2. The results of behavioral assessment are shown in Table 2:

[0160] Table 2

[0161] serial number 1 2 3 4 5 6 average value Standard error Model Group 4 4 3 5 4 3 3.8 0.8 S1 2 2 2 2 1 3 2.0 0.6 S3 3 4 1 2 3 2 2.5 1.0 Sham operation group 0 0 0 0 0 0 0.0 0.0

[0162] It can be seen from Table 2 that the synthetic peptide provided by the present invention has physiological activity. The behavioral score of rats with cerebral ischemia injected with normal saline was 3.8±0.8; the score of rats with cerebral ischemia injected with 3 mg / kg beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val (S3) was 2.5±1.0; as a comparison, the score of rats with cerebral ischemia intravenously administered with 3 mg / kg NA1 was 2.0±0.6. The result of the sham operation group as a control was 0.0±0.0. Compared with the model group, S3 has obvious biological activity, and there is no statistical difference between S3 and S1.

[0163] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A neuroprotective polypeptide compound, characterized in that: A polypeptide and a salt thereof having the following chemical formula: beta-Ala-His-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val or Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-beta-Ala-His.

2. Use of the neuroprotective polypeptide compound according to claim 1 in the preparation of a drug for treating ischemic stroke.

3. The use according to claim 2, characterized in that: The medicine is for injection, oral administration, sublingual administration, spray administration or anal administration.

Citation Information

Patent Citations

  • Process for isolating rubbers

    EP0002015A1

  • Model systems and treatment regimes for treatment of neurological disease

    US8940699B2

  • Model systems and treatment regimes for treatment of neurological disease

    CN102458441A

  • Intelligent cerebral stroke drug carrier for ROS (reactive oxygen species) response and preparation method of drug carrier

    CN106267149A

  • Multifunctional polypeptide and its application in field of medicines

    CN113121641A